CRO Novotech inks partnership deal with the Asian Eye Institute

eyes
Australia-based CRO Novotech has inked a partnership deal with the Asian Eye Institute for clinical research with the Philippines-based ophthalmology firm. (Pixabay)

Australia-based CRO Novotech has inked a partnership deal with the Asian Eye Institute for clinical research with the Philippines-based ophthalmology firm.

Under terms of the partnership, the institute will provide professional and clinical trial expertise to studies being managed by Novotech. Services will cover feasibility, principal investigator selection, patient recruitment and execution of ophthalmology studies, the company said.

Financial terms of the agreement weren’t disclosed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The Asian Eye Institute has run more than 100 clinical trials and touts its investigator-led research site as one of the best in the region for research in ophthalmic drugs and devices. It treats about 60,000 patients each year at clinics located throughout the Philippines, which has a population of about 107 million.

RELATED: Australian CRO Novotech firms up its Hong Kong presence

Novotech said it will have dedicated clinicians working inside the institute to support the clinical trial processes for its biopharma clients.

“Novotech is the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region,” Yooni Kim, M.D., executive director of Novotech’s Asia operations, said in a statement. “We have offices and teams on the ground as well as MOUs and long-term relationships with major hospitals that directly benefit our clients."

Novotech, which was founded in 1996, bills itself as Australia’s largest contract drug developer with offices in 11 countries across the region.

Suggested Articles

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.

Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.